ALZFORUM | NETWORKING FOR A CURE
4 days ago — Most scientists agree that for amyloidosis to ignite, both ApoE and microglia need to be present. A new study presents a mechanistic link between the two. Scientists report that ApoE and Aβ both aggregate within microglial lysosomes, and that these intracellular liaisons ultimately seed amyloid plaques.
Leqembi - ALZFORUM
Overview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...
Brain Changes Speak Volumes About Normal Aging and
Jun 7, 2013 — Most areas of the brain were affected, with the hippocampus and amygdala losing about 1 percent and cortical regions about 0.5 percent. "There are a lot of changes in the brain that cannot be ascribed to incipient dementia," said Fjell. "These changes could be due to either normal aging or other pathologies that we are not able to detect."
All News - ALZFORUM
6 days ago — Some Plasma Proteins Bolster Phagocytosis and Metabolism in Microglia. Add To My AlzForum. 1 Comment. 29 Oct 2024. In certain regions of the brain, microglia internalize proteins from the plasma. At least one of these peripheral …
Paper Alert: p-Tau217 Blood Test Predicts Plaques, Tangles
Jan 24, 2024 — Plasma p-tau 217 measured with this assay distinguished amyloid-positive participants from those without plaques with areas under the curve of 0.92 to 0.96 across the three cohorts. AUC measures specificity and sensitivity, with 1 being perfect. The assay was similarly accurate in detecting tau pathology, with AUCs of 0.93 to 0.97.
Relyvrio - ALZFORUM
Overview. Name: Relyvrio Synonyms: Albrioza, AMX0035 Therapy Type: Combination, Small Molecule Target Type: Other Condition(s): Amyotrophic Lateral Sclerosis, Alzheimer's Disease U.S. FDA Status: Amyotrophic Lateral Sclerosis (Approved), Alzheimer's Disease (Phase 2) Company: Amylyx Pharmaceuticals Inc Approved for: ALS Background. AMX0035 is a proprietary, oral combination of two drugs ...
Bepranemab - ALZFORUM
Jan 23, 2022 — Overview. Name: Bepranemab Synonyms: UCB0107 , UCB 0107 , Antibody D Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Progressive Supranuclear Palsy, Alzheimer's Disease U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Company: Hoffmann-La Roche, UCB S.A. Background. This humanized, monoclonal IgG4 antibody binds to the central region ...
Memantine - ALZFORUM
Memantine's side effects include fatigue, increases in blood pressure, dizziness, headache, constipation, confusion, and sleepiness, among others. Memantine is the only FDA-approved drug for the treatment of Alzheimer's disease that is not an acetyl cholinesterase inhibitor. The drug is a noncompetitive, low- to medium-affinity antagonist of ...
Rivastigmine - ALZFORUM
Nov 2, 2022 — Rivastigmine's side effects are consistent with class effects of cholinesterase inhibition. They include most commonly nausea, vomiting, diarrhea, and loss of appetite; less frequently, agitation, depression, dizziness, fatigue/sleeplessness, and others. Side effects tend to be strongest in the beginning weeks, when the dose is titrated up to ...
Bryostatin 1 - ALZFORUM
Oct 18, 2023 — It has potent and broad antitumor activity. Bryostatin 1 activates protein kinase C family members, with nanomolar potency for PKC1α and ε isotypes. In the central nervous system, bryostatin 1 activation of PKC boosts synthesis and secretion of the neurotrophic factor BDNF, a synaptic growth factor linked to learning and memory (reviewed in ...